In-vitro evaluation of the immunomodulatory effects of Baricitinib: Implication for COVID-19 therapy is a research paper published in Journal of Infection (2021). On theSindex it has a DataRank of 0. It has been cited 57 times.
Scored on demand from live citation data
Linked data & code
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
National Institute of Allergy and Infectious Diseases
Grant: 653316
National Institute of Allergy and Infectious Diseases
Grant: 75N9301900065
National Institute of Allergy and Infectious Diseases
Grant: 871029
European Virus Archive GLOBAL
Eli Lilly and Company
Grant: 2889530D-8A27-4FD8-A3CA-9384E65939F7
Eli Lilly and Company
Grant: COVID-2020-12371675
Eli Lilly and Company
Grant: COVID-2020-12371735
Eli Lilly and Company
Grant: COVID-2020-12371817
Gilead Sciences
Meso Scale Diagnostics
Ministry of Health
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals
Additional file 1 of Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
Additional file 1 of Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
Additional file 2 of Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis
Additional file 2 of Efficacy and safety of baricitinib for the treatment of hospitalized adults with COVID-19: a systematic review and meta-analysis